Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
Light, Science & Applications
|
January 7, 2024
Highly efficient and aberration-free off-plane grating spectrometer and monochromator for EUV-soft X-ray applications
Jie Li, Kui Li, Xiaoshi Zhang, et al.
Medcomm
|
February 19, 2025
Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAF<sup>V600</sup>-mutant advanced melanoma: a multicenter cohort study
Junwan Wu, Qiuyue Ding, Qiong Zhang, et al.
Journal for Immunotherapy of Cancer
|
November 23, 2019
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
Xuanye Zhang, Yixin Zhou, Chen Chen, et al.
Cancer Immunology, Immunotherapy : CII
|
March 2, 2024
Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy
Lujun Shen, Hongtong Tan, Juan Nie, et al.
Medcomm
|
April 27, 2026
Optimal Adjuvant Therapy Selection for Chinese BRAF V600-Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies
Rongcheng Zhang, Yao Liang, Jingjing Li, et al.
NPJ Precision Oncology
|
July 12, 2025
Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study
Zhenlin Hou, Leen Liao, Weiwei Xiao, et al.
Cancer Research
|
July 4, 2018
<i>PDSS2</i> Deficiency Induces Hepatocarcinogenesis by Decreasing Mitochondrial Respiration and Reprogramming Glucose Metabolism
Yan Li, Shuhai Lin, Lei Li, et al.
Frontiers in Immunology
|
October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Annals of Surgical Oncology
|
May 12, 2018
Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients
ChuanLiang Cui, Bin Lian, Li Zhou, et al.
Translational Oncology
|
April 14, 2019
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
Light, Science & Applications
|
January 7, 2024
Highly efficient and aberration-free off-plane grating spectrometer and monochromator for EUV-soft X-ray applications
Jie Li, Kui Li, Xiaoshi Zhang, et al.
Medcomm
|
February 19, 2025
Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAF<sup>V600</sup>-mutant advanced melanoma: a multicenter cohort study
Junwan Wu, Qiuyue Ding, Qiong Zhang, et al.
Journal for Immunotherapy of Cancer
|
November 23, 2019
Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition
Xuanye Zhang, Yixin Zhou, Chen Chen, et al.
Cancer Immunology, Immunotherapy : CII
|
March 2, 2024
Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy
Lujun Shen, Hongtong Tan, Juan Nie, et al.
Medcomm
|
April 27, 2026
Optimal Adjuvant Therapy Selection for Chinese BRAF V600-Mutant Stage III Melanoma: A Multicenter Efficacy Comparison of Targeted Agents, Immunotherapy, and Combinatorial Strategies
Rongcheng Zhang, Yao Liang, Jingjing Li, et al.
NPJ Precision Oncology
|
July 12, 2025
Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study
Zhenlin Hou, Leen Liao, Weiwei Xiao, et al.
Cancer Research
|
July 4, 2018
<i>PDSS2</i> Deficiency Induces Hepatocarcinogenesis by Decreasing Mitochondrial Respiration and Reprogramming Glucose Metabolism
Yan Li, Shuhai Lin, Lei Li, et al.
Frontiers in Immunology
|
October 28, 2022
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Annals of Surgical Oncology
|
May 12, 2018
Multifactorial Analysis of Prognostic Factors and Survival Rates Among 706 Mucosal Melanoma Patients
ChuanLiang Cui, Bin Lian, Li Zhou, et al.
Translational Oncology
|
April 14, 2019
A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)
Lu Si, Xiaoshi Zhang, Yongqian Shu, et al.
Page
of 9